January 30, 2017 / 9:20 PM / 3 years ago

BRIEF-Corcept Therapeutics reports Q4 preliminary GAAP earnings per share $0.04

Jan 30 (Reuters) - Corcept Therapeutics Inc

* Corcept Therapeutics announces preliminary fourth quarter and full-year 2016 financial results and corporate update; provides 2017 revenue guidance

* Q4 preliminary GAAP earnings per share $0.04

* Sees FY 2017 revenue $115 million to $125 million

* Q4 revenue $23.8 million versus I/B/E/S view $23.5 million

* Q4 earnings per share view $0.01 — Thomson Reuters I/B/E/S

* Corcept Therapeutics - results expected by year-end in phase 2 trial of proprietary, selective cortisol modulator cort125134 to treat cushing’s syndrome

* Corcept Therapeutics Inc - Phase 1 trials of selective cortisol modulators cort125281 and cort118335 on track to start in Q2 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below